CClinicalTrials.gg
CompletedNCT01176630Updated Feb 27, 2012

Prevalence of Metabolic Syndrome in a Maintenance Hemodialysis Population

An observational study in Metabolic Syndrome, sponsored by Winthrop University Hospital. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-02-27.

Sponsored by Winthrop University Hospital · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
108
Ages
18 Years and older
Sex
All
01

Study summary

The study is a survey to answer the specific question, "What is the prevalence of metabolic syndrome in maintenance hemodialysis patients?" Metabolic syndrome is a cluster of conditions that increase an individual's risk for developing cardiovascular disease and diabetes.

Read the detailed description

Risk factors for metabolic syndrome will be collected for each consented patient. They include elevated serum triglycerides, reduced HDL cholesterol, hypertension, elevated fasting blood sugar concentration and abdominal obesity. The investigator will measure waist circumference of each consented patient in a secure area according to standardized procedures. The other data is available from the patient's medical record.

02

Conditions studied

  • Metabolic Syndrome

Keywords

  • metabolic syndrome, ESRD patient
03

In context

Metabolic Syndrome

1,964 studies on the registry are indexed under Metabolic Syndrome; 330 are open to participants now.

This study's enrollment of 108 is below the median of 200 across 458 observational studies indexed under Metabolic Syndrome.

Browse Metabolic Syndrome studies →

Lead sponsor

Winthrop University Hospital is the lead sponsor of 41 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All study subjects are on maintenance hemodialysis

Inclusion criteria

  • Patients undergoing maintenance hemodialysis equal to or greater than 3 months
  • Patient at lest 18 years of age
  • Availability of all data in the medical record for classification of the metabolic syndrome, including serum triglycerides, serum HDL-cholesterol, systolic BP and diastolic BP, and serum glucose

Exclusion criteria

Exclusion Criteria:

  • Patients unwilling or unable to give informed consent to participate
  • Patients with a history of thyroid disease
  • Patients unable to stand upright
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
108 participants (actual)
06

What researchers measure

Primary outcomes

  1. Percent of maintenance patients with at least three risk factors of metabolic syndrome

    Time frame: 6 months

07

Study locations

1 site
  • Winthrop University Hospital Outpatient Dialysis Unit
    Mineola, New York 11501, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 27, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01176630
Lead sponsor
Winthrop University Hospital
Responsible party
Mary Schanler (Administrative Dietitian, Winthrop University Hospital) — Principal investigator
First posted
Aug 6, 2010
Start date
Aug 2010
Primary completion
Dec 2010
Completion
Dec 2010
Last update
Feb 27, 2012

Study contacts

Mary Schanler, MS, RD
principal investigator · Winthrop University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion